Edition:
United Kingdom

Acceleron Pharma Inc (XLRN.OQ)

XLRN.OQ on NASDAQ Stock Exchange Global Market

35.59USD
20 Apr 2018
Change (% chg)

$-0.32 (-0.89%)
Prev Close
$35.91
Open
$35.76
Day's High
$36.18
Day's Low
$35.24
Volume
91,438
Avg. Vol
124,943
52-wk High
$46.51
52-wk Low
$24.48

Chart for

About

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta... (more)

Overall

Beta: 1.66
Market Cap(Mil.): $1,680.20
Shares Outstanding(Mil.): 44.04
Dividend: --
Yield (%): --

Financials

  XLRN.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -2.49 -- --
ROI: -41.85 1.58 14.38
ROE: -44.00 2.41 16.07

BRIEF-Acceleron Pharma Q4 Loss Per Share $‍0.62​

* ACCELERON REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS

27 Feb 2018

BRIEF-Acceleron plans to initiate part 2 of ACE-083 FSHD phase 2 trial during Q2 of 2018

* ACCELERON PHARMA INC - PLANS TO INITIATE PART 2 OF ACE-083 FSHD PHASE 2 TRIAL DURING Q2 OF 2018

08 Jan 2018

BRIEF-BioAg Alliance Announces Updated Research And Development Pipeline

* BIOAG ALLIANCE - ANNOUNCED UPDATED RESEARCH AND DEVELOPMENT PIPELINE

04 Jan 2018

BRIEF-Acceleron ‍expects to initiate a phase 2 trial in 1H 2018​

* Acceleron announces preclinical results in pulmonary arterial hypertension at the American Heart Association 2017 Scientific Sessions

14 Nov 2017

BRIEF-Acceleron Pharma qtrly net loss per share $0.65

* Acceleron Pharma reports third quarter 2017 operational and financial results

07 Nov 2017

Earnings vs. Estimates